These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

89 related items for PubMed ID: 2428468

  • 1. Preclinical trials with combinations and conjugates of T101 monoclonal antibody and doxorubicin.
    Dillman RO, Shawler DL, Johnson DE, Meyer DL, Koziol JA, Frincke JM.
    Cancer Res; 1986 Oct; 46(10):4886-91. PubMed ID: 2428468
    [Abstract] [Full Text] [Related]

  • 2. Preclinical trials using an immunoconjugate of T101 and methotrexate in an athymic mouse/human T-cell tumor model.
    Shawler DL, Johnson DE, Sweet MD, Myers LJ, Tudor SD, Beidler DE, Koziol JA, Dillman RO.
    J Biol Response Mod; 1988 Dec; 7(6):608-18. PubMed ID: 3265148
    [Abstract] [Full Text] [Related]

  • 3. Cytotoxic effect of anti-Mr 67,000 protein immunotoxins on human tumors in a nude mouse model.
    Weil-Hillman G, Runge W, Jansen FK, Vallera DA.
    Cancer Res; 1985 Mar; 45(3):1328-36. PubMed ID: 3971376
    [Abstract] [Full Text] [Related]

  • 4. Significance of antigen, drug, and tumor cell targets in the preclinical evaluation of doxorubicin, daunorubicin, methotrexate, and mitomycin-C monoclonal antibody immunoconjugates.
    Dillman RO, Johnson DE, Ogden J, Beidler D.
    Mol Biother; 1989 Mar; 1(5):250-5. PubMed ID: 2515870
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of human T-cell tumor growth by T101-ricin A-chain in an athymic mouse model.
    Leonard JE, Johnson DE, Shawler DL, Dillman RO.
    Cancer Res; 1988 Sep 01; 48(17):4862-7. PubMed ID: 3261627
    [Abstract] [Full Text] [Related]

  • 6. Superiority of an acid-labile daunorubicin-monoclonal antibody immunoconjugate compared to free drug.
    Dillman RO, Johnson DE, Shawler DL, Koziol JA.
    Cancer Res; 1988 Nov 01; 48(21):6097-102. PubMed ID: 3262420
    [Abstract] [Full Text] [Related]

  • 7. Antigen-specific activity of carcinoma-reactive BR64-doxorubicin conjugates evaluated in vitro and in human tumor xenograft models.
    Trail PA, Willner D, Lasch SJ, Henderson AJ, Greenfield RS, King D, Zoeckler ME, Braslawsky GR.
    Cancer Res; 1992 Oct 15; 52(20):5693-700. PubMed ID: 1382845
    [Abstract] [Full Text] [Related]

  • 8. Disposition of conjugate-bound and free doxorubicin in tumor-bearing mice following administration of a BR96-doxorubicin immunoconjugate (BMS 182248).
    Mosure KW, Henderson AJ, Klunk LJ, Knipe JO.
    Cancer Chemother Pharmacol; 1997 Oct 15; 40(3):251-8. PubMed ID: 9219510
    [Abstract] [Full Text] [Related]

  • 9. Monoclonal antibody 44-3A6 doxorubicin immunoconjugates: comparative in vitro anti-tumor efficacy of different conjugation methods.
    Sinkule JA, Rosen ST, Radosevich JA.
    Tumour Biol; 1991 Oct 15; 12(4):198-206. PubMed ID: 1651554
    [Abstract] [Full Text] [Related]

  • 10. Doxorubicin: monoclonal antibody conjugate for therapy of human cervical carcinoma.
    Yeh MY, Roffler SR, Yu MH.
    Int J Cancer; 1992 May 08; 51(2):274-82. PubMed ID: 1568795
    [Abstract] [Full Text] [Related]

  • 11. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
    Park JW, Hong K, Kirpotin DB, Colbern G, Shalaby R, Baselga J, Shao Y, Nielsen UB, Marks JD, Moore D, Papahadjopoulos D, Benz CC.
    Clin Cancer Res; 2002 Apr 08; 8(4):1172-81. PubMed ID: 11948130
    [Abstract] [Full Text] [Related]

  • 12. Immune interferon modulation of in vitro murine anti-human T cell monoclonal antibody-mediated cytotoxicity.
    Dillman RO, Johnson DE, Shawler DL.
    J Immunol; 1986 Jan 08; 136(2):728-31. PubMed ID: 3079792
    [Abstract] [Full Text] [Related]

  • 13. Cure of SCID mice bearing human B-lymphoma xenografts by an anti-CD74 antibody-anthracycline drug conjugate.
    Griffiths GL, Mattes MJ, Stein R, Govindan SV, Horak ID, Hansen HJ, Goldenberg DM.
    Clin Cancer Res; 2003 Dec 15; 9(17):6567-71. PubMed ID: 14695162
    [Abstract] [Full Text] [Related]

  • 14. In vitro and in vivo activities of a doxorubicin prodrug in combination with monoclonal antibody beta-lactamase conjugates.
    Svensson HP, Vrudhula VM, Emswiler JE, MacMaster JF, Cosand WL, Senter PD, Wallace PM.
    Cancer Res; 1995 Jun 01; 55(11):2357-65. PubMed ID: 7757987
    [Abstract] [Full Text] [Related]

  • 15. Prevention of radiolysis of monoclonal antibody during labeling.
    Chakrabarti MC, Le N, Paik CH, De Graff WG, Carrasquillo JA.
    J Nucl Med; 1996 Aug 01; 37(8):1384-8. PubMed ID: 8708780
    [Abstract] [Full Text] [Related]

  • 16. Therapeutic efficacy of a doxorubicin immunoconjugate in a preclinical model of spontaneous metastatic human melanoma.
    Sivam GP, Martin PJ, Reisfeld RA, Mueller BM.
    Cancer Res; 1995 Jun 01; 55(11):2352-6. PubMed ID: 7757986
    [Abstract] [Full Text] [Related]

  • 17. Effect of linker variation on the stability, potency, and efficacy of carcinoma-reactive BR64-doxorubicin immunoconjugates.
    Trail PA, Willner D, Knipe J, Henderson AJ, Lasch SJ, Zoeckler ME, TrailSmith MD, Doyle TW, King HD, Casazza AM, Braslawsky GR, Brown J, Hofstead SJ, Greenfield RS, Firestone RA, Mosure K, Kadow KF, Yang MB, Hellström KE, Hellström I.
    Cancer Res; 1997 Jan 01; 57(1):100-5. PubMed ID: 8988048
    [Abstract] [Full Text] [Related]

  • 18. Induction of in vitro and in vivo antigenic modulation by the anti-human T-cell monoclonal antibody T101.
    Shawler DL, Miceli MC, Wormsley SB, Royston I, Dillman RO.
    Cancer Res; 1984 Dec 01; 44(12 Pt 1):5921-7. PubMed ID: 6333922
    [Abstract] [Full Text] [Related]

  • 19. Poly(ethylene glycol)-poly(ester-carbonate) block copolymers carrying PEG-peptidyl-doxorubicin pendant side chains: synthesis and evaluation as anticancer conjugates.
    Andersson L, Davies J, Duncan R, Ferruti P, Ford J, Kneller S, Mendichi R, Pasut G, Schiavon O, Summerford C, Tirk A, Veronese FM, Vincenzi V, Wu G.
    Biomacromolecules; 2005 Dec 01; 6(2):914-26. PubMed ID: 15762660
    [Abstract] [Full Text] [Related]

  • 20. BR96-DOX immunoconjugate targeting of chemotherapy in brain tumor models.
    Muldoon LL, Neuwelt EA.
    J Neurooncol; 2003 Oct 01; 65(1):49-62. PubMed ID: 14649885
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.